Enkang Pharma

恩康药业

Enkang Pharma

Biotech/Healthcare

Enkang Pharmaceuticals develops innovative oncology therapeutics, focusing on novel cancer drug platforms and drug discovery. It has an inhaled liposomal formulation platform and a DRIP (DNA replication initiation protein) inhibitor-based screening platform for targeted oncology drugs.

Latest round: Series B Extension+ (2024)

Source: ChinaBulls — chinabulls.com

Last updated 2024-12-01